Readouts Terminal

Today's biotech news, and what it means for each Thesis.

Live news, catalysts and FDA decisions for 200+ public biotech companies.

Follow companies to see at a glance whether their Thesis still holds.Start free trial

Just in · 8

9:20 PM ETIONS

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

Ionis Pharmaceuticals, Inc.

+2.3%
7:30 PM ETAAPG

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Ascentage Pharma Group Internat

+3.0%
8:50 AM ETMBRX

Moleculin Biotech completes enrollment in AML trial phase

Moleculin Biotech, Inc.

+16.8%
8:30 AM ETRCUS

Arcus: ARC-20 casdatifan cohort data; PEAK-20 start planned Q4 2026; tivozanib registrational trial planned

Arcus Biosciences, Inc.

+7.3%
8:30 AM ETMBOT

Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio

Microbot Medical Inc.

-0.6%

Supports the Thesis · 20

Weighs on the Thesis · 7

Other news · 24

DRTS

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

Alpha Tau Medical Ltd.

Oct 19
SMMT

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Summit Therapeutics Inc.

Oct 19
IDYA

IDEAYA: ESMO 2026 darovasertib data; first-line NDA submission under RTOR in progress

IDEAYA Biosciences, Inc.

Oct 19
BLTE

Belite Bio moves to Nasdaq Global Select Market

Belite Bio, Inc

Oct 19
ALT

Altimmune: IMPACT data at AASLD; pemvidutide hamster alcohol study; RESTORE enrollment complete

Altimmune, Inc.

Oct 19
AVBP

ArriVent: FURTHER Phase 1b firmonertinib data published in Cancer Cell; ALPACCA enrolling

ArriVent BioPharma, Inc.

Oct 19
DCTH

Delcath: CS-PHP uveal melanoma analysis; tebentafusp registry poster; DELUMA breast trial; Del-Liver update set

Delcath Systems, Inc.

Oct 19
EVAX

EVX-01 three-year follow-up: responses sustained, no progression

Evaxion A/S

Oct 19
IOVA

Iovance: final IOV-COM-202 Phase 2 data at ESMO; five abstracts; MSKCC UPS/DDLPS pilot

Iovance Biotherapeutics, Inc.

Oct 19
OSTX

OS Therapies: $7.2M warrant inducement; Herlystic RMAT resubmitted; CNPV letter accepted

OS Therapies Incorporated

Oct 19

Built for investors who own too many positions to track manually.

The problem isn't “I don't know how to read an 8-K.” The problem is “I own 20 biotech stocks, each one binary enough to double or halve on a single FDA letter, and I don't have time to continuously reassess each thesis.” readouts.io pays for itself the first time it catches a thesis change you would have missed.

Early adopter
$20/ month$30

7-day free trial, no card needed — then $20/month forever, locked in as an early adopter

Every covered company, one Thesis — updated as the story changes. Follow what you own, ask what you need to know.

With a subscription

Why each checklist item is in its state
Strong, inconclusive and weak outcomes for each next decision
The reasoning behind every entry in the Thesis history
Competitive landscape
Email alerts when a Thesis you follow changes
Ask any question about any company

Free for everyone

The Thesis and its status (Intact, Challenged or Broken) for every covered company
The Thesis checklist and next decision point, where available
Every catalyst date, linked to its source
The dated history of each Thesis
Pipeline, drug pages and the catalyst calendar
Track your first thesis

Free to sign up — your 7-day trial starts immediately, no card needed. Nothing is charged unless you choose to subscribe.